Avid Bioservices (Avid Bioservices) Cash And Cash Equivalents : $30.7 Mil (As of Jan. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Avid Bioservices Cash And Cash Equivalents?

Avid Bioservices's quarterly cash and cash equivalents increased from Jul. 2023 ($24.90 Mil) to Oct. 2023 ($31.42 Mil) but then stayed the same from Oct. 2023 ($31.42 Mil) to Jan. 2024 ($30.71 Mil).

Avid Bioservices's annual cash and cash equivalents declined from Apr. 2021 ($169.92 Mil) to Apr. 2022 ($126.17 Mil) and declined from Apr. 2022 ($126.17 Mil) to Apr. 2023 ($38.54 Mil).

Avid Bioservices Cash And Cash Equivalents Historical Data

The historical data trend for Avid Bioservices's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices Cash And Cash Equivalents Chart

Avid Bioservices Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Cash And Cash Equivalents

Get a 7-Day Free Trial

32.35

36.26

169.92

126.17

38.54

Avid Bioservices Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash And Cash Equivalents	Get a 7-Day Free Trial															59.92	38.54	24.90	31.42	30.71

Avid Bioservices Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Avid Bioservices (NAS:CDMO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Avid Bioservices Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Avid Bioservices (Avid Bioservices) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

TEHN:Germany

Address

14191 Myford Road, Tustin, CA, USA, 92780

Website

https://www.avidbio.com

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Executives

Matthew R. Kwietniak	officer: Chief Commercial Officer	14191 MYFORD ROAD, TUSTIN CA 92780
Richard A. Richieri	officer: Chief Operations Officer	14191 MYFORD ROAD, TUSTIN CA 92780
Daniel Ryan Hart	officer: Chief Financial Officer	2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780
Mark R Ziebell	officer: V.P., General Counsel	14282 FRANKLIN AVENUE, TUSTIN CA 92780
Richard B Hancock	director	14282 FRANKLIN AVE., TUSTIN CA 92780
Joseph Carleone	director	3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169
Nicholas Stewart Green	director, officer: President & CEO	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Gregory Sargen	director
Esther M. Alegria	director	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Mark R Bamforth	director	500 KENDALL ST., CAMBRIDGE MA 02142
Jeanne Thoma	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Joel Mccomb	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Stephen Michael Hedberg	officer: Principal Fin. & Acct. Officer	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780